Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8168794 | Pim kinase inhibitors and methods of their use The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically accep... | 05/01/2012 |
| 8026367 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined in the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the inventio... | 09/27/2011 |
| 8022223 | 2-aminopyridine analogs as glucokinase activators Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characteriz... | 09/20/2011 |
| 8022222 | Glucokinase activators Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of gluc... | 09/20/2011 |
| 7390907 | Vanilloid receptor ligands and their use in treatments Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascu... | 06/24/2008 |
| 7326728 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula ... | 02/05/2008 |
| 7262196 | Tri(cyclo) substituted amide glucokinase activator compounds Compounds of Formula (I): or pharmaceutically acceptable salts or N-oxides thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes. ... | 08/28/2007 |
| 7253197 | Aminothiazole derivatives Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in the specification, and the compounds, salts and esters... | 08/07/2007 |
| 7241781 | Thiazolyl inhibitors of Tec family tyrosine kinases Novel thiazolyl compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of Tec family tyrosine kinase-associated disorders such as cancer, immunologic disorders and allergic disorders. | 07/10/2007 |
| 7214681 | Tri(cyclo) substituted amide compounds Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes. ... | 05/08/2007 |
| 7214678 | Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification. | 05/08/2007 |
| 7183302 | Iminothiazolidinones as inhibitors of HCV replication Compounds having the structure of formula I are described wherein R, R′, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) repl... | 02/27/2007 |
| 7109202 | Aminothaizoles and their use as adenosine receptor antagonists Compounds of formula (I) in free or salt form, where A is a C6-C15 monovalent aromatic group. R1 is hydrogen, phenyl optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, C1–C8 | 09/19/2006 |
| 7091223 | Cyclic protein tyrosine kinase inhibitors Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders. ... | 08/15/2006 |
| 7084160 | Heterocyclic inhibitors of kinases The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2... | 08/01/2006 |
| 7067516 | Serine protease inhibitors Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents. ... | 06/27/2006 |
| RE39140 | Heterocyclic compounds Novel heterocyclic compounds of the formula wherein, R1 represents a hydrogen atom or an alkyl group, A represents an ethylene group which may be substituted by alkyl or a trimethylene group which may be substituted by... | 06/20/2006 |
| RE39127 | Heterocyclic compounds Novel heterocyclic compounds of the formula wherein, R1 represents a hydrogen atom or an alkyl group, A represents an ethylene group which may be substituted by alkyl or a trimethylene group which may be substituted by... | 06/13/2006 |
| RE39129 | Heterocyclic compounds Novel heterocyclic compounds of the formula wherein, R1 represents a hydrogen atom or an alkyl group, A represents an ethylene group which may be substituted by alkyl or a trimethylene group which may be substituted by... | 06/13/2006 |
| RE39130 | Heterocyclic compounds Novel heterocyclic compounds of the formula wherein, R1 represents a hydrogen atom or an alkyl group, A represents an ethylene group which may be substituted by alkyl or a trimethylene group which may be substituted by... | 06/13/2006 |
| RE39131 | Heterocyclic compounds Novel heterocyclic compounds of the formula wherein, R1 represents a hydrogen atoms or an alkyl group, A represents an ethylene group which may be substituted by alkyl or a trimethylene group which may be substituted b... | 06/13/2006 |
| 7037926 | Thiazolyl inhibitors of Tec family tyrosine kinases Novel thiazolyl compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of Tec family tyrosine kinase-associated disorders such as cancer, immunologic disorders and allergic disorders. | 05/02/2006 |
| 7037880 | Ethylene derivatives and pesticides containing said derivatives Ethylene derivatives of formula (I): where Q is an unsubstituted or substituted phenyl or heterocyclic group, especially a 4-thiazolyl, 1- or 3-pyrazolyl, 1,3-oxazol-4-yl, phenyl or pyridyl group; E is a substituent su... | 05/02/2006 |
| 6995181 | Modulators of the glucocorticoid receptor and method Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the s... | 02/07/2006 |
| 6979694 | Cyclic protein tyrosine kinase inhibitors Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders. ... | 12/27/2005 |
| 6911545 | Crystals of glucokinase and methods of growing them Crystalline forms of mammalian Gluckokinase of sufficient size and quality to obtain structural data by X-ray crystallography are presented. Methods of growing such crystals are also disclosed. ... | 06/28/2005 |
| 6900237 | Sulfonamide compounds as protease inhibitors The present invention relates to novel cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making. ... | 05/31/2005 |
| 6878728 | Inhibitors of aspartyl protease The invention provides novel compounds of formula (I) wherein all variables are as defined in the specification, that are useful as inhibitors of aspartyl proteases. ... | 04/12/2005 |
| 6875767 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors The present invention relates to compounds having the formula I: which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to tre... | 04/05/2005 |
| 6852717 | Compounds useful as anti-inflammatory agents Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds. ... | 02/08/2005 |
| 6849639 | Integrin inhibitors and their methods of use The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as a αvβ3, α | 02/01/2005 |
| 6774229 | Coupling condensation synthesis of heterocycles The invention relates to a process for the preparation of heterocycles, characterised in that the following components: i) a propargyl derivative of the general structural formula I a wherein Het is an optional... | 08/10/2004 |
| 6762196 | Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase The present invention relates to the use of 2-amino-4-pyridylmethyl thiazoline derivatives of formula (I) wherein either R1═R2═Cl or (C1-C4)alkyl, or hydroxy; or (C1 | 07/13/2004 |
| 6747146 | Method of producing nitroguanidine- and nitroenamine derivatives Method of producing compounds of formula wherein R1 is hydrogen or C1-C4-alkyl; R2 is hydrogen, C1-C8-alkyl, C3-C6-cyc... | 06/08/2004 |
| 6737382 | Insecticidal aminothiazole derivatives Insecticidal aminothiazole derivatives and the use as an insecticide and acaricide of the compounds of formula (1): wherein R1 is cyano or fluoroalkyl, R2 is halogen, SCN or aryl, R3 is H... | 05/18/2004 |
| 6727269 | 2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivatives of general formula (I), their preparation methods and their use as medicines, in particular for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is/a... | 04/27/2004 |
| 6720347 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases Compounds of the formula and pharmaceutically acceptable salts thereof, wherein R1 and A are defined herein, are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example... | 04/13/2004 |
| 6720427 | Thiazole derivatives The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inh... | 04/13/2004 |
| 6667401 | Method for producing heterocyclic compounds The present invention relates to a process for the preparation of compounds of the formula (I) ##STR1## in which R1, A, D, X and Z have the meanings given in the description, by reacting compounds of the formula (II) ##STR2## in wh... | 12/23/2003 |
| 6593327 | Compounds and compositions as protease inhibitors The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... | 07/15/2003 |
